Demand for excipients to rise; TheraBiogen launches migraine nasal spray;

> In one measure of the increasing importance of drug delivery, the U.S. demand for excipients will rise 3.9 percent a year to $1.9 billion in 2015. Excipients can, among other things, control the release of medication. Story

> TheraBiogen has launched a nasal spray for migraine relief. Item

> Biogen Idec has obtained the European Commission's approval for its Avonex Pen for patients who are suffering from relapsing multiple sclerosis. Avonex Pen is a single-use, once-a-week, intramuscular autoinjector. The needle is hidden prior to injection. More here

> Helicon Group's electronic drug delivery device for syringes successful in tests. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.